These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 16035118)

  • 1. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
    Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
    Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
    Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C
    Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.